Drugs / ASP7991
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01872026 | Dec 2012 → Jun 2013 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01872013 | Nov 2012 → Feb 2013 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01675518 | Jan → Jun 2012 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02133404 | Mar → Nov 2014 | secondary hyperparathyroidism | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP7991 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02133404 ↗ |
| Action | Activate | “Calcium sensing receptor positive allosteric modulator” CHEMBL3545100 ↗ |
| Route | Oral | “single oral administration” NCT01675518 ↗ |
| Target | CASR | “Calcium sensing receptor positive allosteric modulator” CHEMBL3545100 ↗ |